[Pharm-policy] Myriad and HPC2 prostate cancer gene

[James Love]

Apparently Myriad will also have rights to the HPC2 prostate cancer
gene.  

http://www.myriad.com/pr/20001004.html

MYRIAD GENETICS PRESENTS PROSTATE CANCER GENE AT ANNUAL ASHG MEETING 

Philadelphia, PA, October  4, 2000

Myriad Genetics, Inc. (NASDAQ: MYGN) today presented studies which led
to the discovery of the HPC2 prostate cancer gene at the annual meeting
of the American Society of Human Genetics (ASHG) in Philadelphia.  Dr.
Sean V. Tavtigian, Vice President and Head of Cancer Research at Myriad
Genetics, presented a detailed study that utilized Myriad's extensive
genomics resources,including the unmatched genealogical and medical
database records that were key to the isolation and cloning of the
prostate cancer predisposition gene, HPC2.  

  [snip]

-- 
James Love  mailto:love@cptech.org http://www.cptech.org
Consumer Project on Technology, P.O. Box 19367, Washington, DC 20036
voice 1.202.387.8030  fax  1.202.234.5176